338 related articles for article (PubMed ID: 17210514)
1. Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.
Singh ZN; Huo D; Anastasi J; Smith SM; Karrison T; Le Beau MM; Larson RA; Vardiman JW
Am J Clin Pathol; 2007 Feb; 127(2):197-205. PubMed ID: 17210514
[TBL] [Abstract][Full Text] [Related]
2. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
3. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes.
Kao JM; McMillan A; Greenberg PL
Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988
[TBL] [Abstract][Full Text] [Related]
4. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
5. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?
Larson RA
Best Pract Res Clin Haematol; 2007 Mar; 20(1):29-37. PubMed ID: 17336252
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
7. World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with de novo primary myelodysplastic syndromes.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Dambruoso I; Lazzarino M; Bernasconi C
Br J Haematol; 2007 May; 137(3):193-205. PubMed ID: 17408458
[TBL] [Abstract][Full Text] [Related]
8. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis.
Müller-Berndorff H; Haas PS; Kunzmann R; Schulte-Mönting J; Lübbert M
Ann Hematol; 2006 Aug; 85(8):502-13. PubMed ID: 16715299
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations.
Arber DA; Slovak ML; Popplewell L; Bedell V; Ikle D; Rowley JD;
Am J Clin Pathol; 2002 Feb; 117(2):306-13. PubMed ID: 11863228
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
12. Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Dambruoso I; Zappatore R
Am J Hematol; 2013 Feb; 88(2):120-9. PubMed ID: 23349006
[TBL] [Abstract][Full Text] [Related]
13. [Myelodysplastic syndrome--classification, prognosis and therapy].
Cermák J; Michalová K; Vítek A
Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.
Holtan SG; Santana-Davila R; Dewald GW; Khetterling RP; Knudson RA; Hoyer JD; Chen D; Hanson CA; Porrata L; Tefferi A; Steensma DP
Am J Hematol; 2008 Sep; 83(9):708-13. PubMed ID: 18634051
[TBL] [Abstract][Full Text] [Related]
15. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
[TBL] [Abstract][Full Text] [Related]
16. Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes.
Ohyashiki JH; Iwama H; Yahata N; Ando K; Hayashi S; Shay JW; Ohyashiki K
Clin Cancer Res; 1999 May; 5(5):1155-60. PubMed ID: 10353751
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.
Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM
Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic potential of morphological and cytogenetic indices in patients with myelodysplastic syndrome].
Gritsaev SV; Martynkevich IS; Abdulkadyrov KM; Tiranova SA; Kakaĭ MP; Martynenko LS; Dziavgo LA
Ter Arkh; 2005; 77(7):22-7. PubMed ID: 16116904
[TBL] [Abstract][Full Text] [Related]
19. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
20. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS.
Park MJ; Kim HJ; Kim SH; Kim DH; Kim SJ; Jang JH; Kim K; Kim WS; Jung CW
Eur J Haematol; 2008 Nov; 81(5):364-73. PubMed ID: 18637029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]